A recent review highlighted the use of histamine H2 receptor (H2R) ligands in cancer with two main adjuvant applications: improving antitumor efficacy by regulation of immune response, and preventing toxic adverse effects produced by chemo- or radiotherapy [179]. Here, HRH2 is linked to cancer.